Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 1.00 |
| ▸ | KCNA3 | P22001 | 2/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.57 |
| ▸ | CCKBR | P32239 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29499525 | 1.00 | KCNN4 (1.00) | KCNN4KCNA3CYP19A1OPRK1KCNH2 | |
| SCHEMBL2338372 | 0.84 | KCNN4 (0.72) | KCNN4KCNA3CYP19A1OPRK1KCNH2 | |
| SCHEMBL2392101 | 0.84 | KCNN4 (0.72) | KCNN4KCNA3CYP19A1OPRK1KCNH2 | |
| SCHEMBL2392374 | 0.82 | KCNN4 (0.69) | KCNN4KCNA3CYP19A1OPRK1KCNH2 | |
| SCHEMBL23995584 | 0.81 | KCNN4 (0.68) | KCNN4KCNA3CYP19A1OPRK1KCNH2 | |
| SCHEMBL19951665 | 0.81 | KCNN4 (0.68) | KCNN4KCNA3CYP19A1OPRK1KCNH2 | |
| SCHEMBL28044107 | 0.81 | KCNN4 (0.68) | KCNN4KCNA3CYP19A1OPRK1KCNH2 | |
| SCHEMBL2361042 | 0.80 | KCNN4 (0.67) | KCNN4KCNA3CYP19A1OPRK1KCNH2 | |
| SCHEMBL7789691 | 0.79 | KCNN4 (0.66) | KCNN4KCNA3CYP19A1OPRK1KCNH2 | |
| SCHEMBL29008837 | 0.77 | KCNN4 (0.62) | KCNN4KCNA3CYP19A1OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4259130-B1 | GARDOS CHANNEL INHIBITOR OR OTHER AGENTS FOR USE IN THE TREATMENT AND PREVENTION OF ANAEMIA OF INFLAMMATION | SANQUIN IP B V (NL) | 2026-03-04 | — | — | EP | claimed |
| CN-120154730-A | Use of potassium-calcium activated channel subfamily N member 4 inhibitors for the preparation of a medicament for preventing and treating and/or delaying the progression of an abdominal aortic aneurysm disease process | 南方科技大学 | 2025-06-17 | — | — | CN | claimed |
| US-20240024335-A1 | TREATMENT AND PREVENTION OF ANAEMIA OF INFLAMMATION | Sanquin IP B.V. (NL) | 2024-01-25 | — | — | US | claimed |
| EP-4259130-A1 | TREATMENT AND PREVENTION OF ANAEMIA OF INFLAMMATION | Sanquin IP B.V. (NL) | 2023-10-18 | — | — | EP | claimed |
| CN-116847838-A | Treatment and prevention of inflammatory anaemia | 桑昆专利有限公司 | 2023-10-03 | — | — | CN | claimed |
| US-20230248672-A1 | COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES | ADIMABIO LLC (US) | 2023-08-10 | — | — | US | claimed |
| EP-4181908-A2 | COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES | Adimabio LLC (US) | 2023-05-24 | — | — | EP | claimed |
| CN-115943138-A | Compositions comprising GARDOS channel antagonists and uses thereof | 阿迪玛生物有限责任公司 | 2023-04-07 | — | — | CN | claimed |
| WO-2022175384-A1 | SMALL-MOLECULE AGENTS WITH ANTIVIRAL ACTIVITY AGAINST RNA VIRUSES | FUNDACIÓN UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR (ES) | 2022-08-25 | — | — | WO | claimed |
| WO-2022124900-A1 | TREATMENT AND PREVENTION OF ANAEMIA OF INFLAMMATION | SANQUIN INNOVATIE B.V. (NL) | 2022-06-16 | — | — | WO | claimed |
| US-7235577-B1 | Non-peptide inhibition of T-lymphocyte activation and therapies related thereto | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-06-26 | — | — | US | claimed |
| WO-2007033307-A2 | INHIBITION OF INTERMEDIATE-CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNELS IN THE TREATMENT AND/OR PREVENTION OF ATHEROSCLEROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-22 | — | — | WO | claimed |
| EP-1562590-A4 | COMPOUNDS, METHODS AND DEVICES FOR INHIBITING NEOPROLIFERATIVE CHANGES IN BLOOD VESSEL WALLS | UNIV CALIFORNIA (US) | 2006-04-05 | — | — | EP | claimed |
| EP-1562590-A2 | COMPOUNDS, METHODS AND DEVICES FOR INHIBITING NEOPROLIFERATIVE CHANGES IN BLOOD VESSEL WALLS | The Regents of the University of California (US) | 2005-08-17 | — | — | EP | claimed |
| EP-1248614-A4 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | UNIV CALIFORNIA (US) | 2005-05-04 | — | — | EP | claimed |
| CN-1600384-A | Potassium channel retarder medication coated bracket in blood vessel | UNIV HARBIN MEDICAL (CN) | 2005-03-30 | — | — | CN | claimed |
| US-6803375-B1 | IMMUNOMODULATION IN A MAMMALIAN PATIENT WITHOUT CAUSING SUBSTANTIAL INHIBITION OF CYTOCHROME P-450 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-10-12 | — | — | US | claimed |
| WO-2004039330-A2 | COMPOUNDS, METHODS AND DEVICES FOR INHIBITING NEOPROLIFERATIVE CHANGES IN BLOOD VESSEL WALLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-05-13 | — | — | WO | claimed |
| EP-1248614-A2 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | The Regents of The University of California (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001049663-A2 | NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-07-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248672-A1 | COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES | CACNA1G, CACNA1I, CACNG2 | KCNN4 36/4885KCNA3 83/4885CYP19A1 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.